Nexien Biopharma Stock Probability of Future Pink Sheet Price Finishing Under 0.0186
| NXEN Stock | USD 0.01 0.01 25.00% |
Nexien |
Nexien Biopharma Target Price Odds to finish below 0.0186
The tendency of Nexien Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to stay under $ 0.02 after 90 days |
| 0.01 | 90 days | 0.02 | about 32.21 |
Based on a normal probability distribution, the odds of Nexien Biopharma to stay under $ 0.02 after 90 days from now is about 32.21 (This Nexien Biopharma probability density function shows the probability of Nexien Pink Sheet to fall within a particular range of prices over 90 days) . Probability of Nexien Biopharma price to stay between its current price of $ 0.01 and $ 0.02 at the end of the 90-day period is about 10.46 .
Given the investment horizon of 90 days the pink sheet has the beta coefficient of 3.19 . This indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Nexien Biopharma will likely underperform. In addition to that Nexien Biopharma has an alpha of 4.275, implying that it can generate a 4.28 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Nexien Biopharma Price Density |
| Price |
Predictive Modules for Nexien Biopharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Nexien Biopharma. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Nexien Biopharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Nexien Biopharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Nexien Biopharma is not an exception. The market had few large corrections towards the Nexien Biopharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Nexien Biopharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Nexien Biopharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 4.28 | |
β | Beta against Dow Jones | 3.19 | |
σ | Overall volatility | 0.01 | |
Ir | Information ratio | 0.13 |
Nexien Biopharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Nexien Biopharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Nexien Biopharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Nexien Biopharma is way too risky over 90 days horizon | |
| Nexien Biopharma has some characteristics of a very speculative penny stock | |
| Nexien Biopharma appears to be risky and price may revert if volatility continues | |
| Nexien Biopharma has high likelihood to experience some financial distress in the next 2 years | |
| Nexien Biopharma currently holds 221.73 K in liabilities with Debt to Equity (D/E) ratio of 0.36, which is about average as compared to similar companies. Nexien Biopharma has a current ratio of 0.5, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Nexien Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Nexien Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Nexien Biopharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Nexien to invest in growth at high rates of return. When we think about Nexien Biopharma's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (626.36 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Nexien Biopharma currently holds about 116.9 K in cash with (75.14 K) of positive cash flow from operations. | |
| Roughly 54.0% of Nexien Biopharma outstanding shares are owned by corporate insiders |
Nexien Biopharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Nexien Pink Sheet often depends not only on the future outlook of the current and potential Nexien Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Nexien Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 60.5 M |
Nexien Biopharma Technical Analysis
Nexien Biopharma's future price can be derived by breaking down and analyzing its technical indicators over time. Nexien Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Nexien Biopharma. In general, you should focus on analyzing Nexien Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
Nexien Biopharma Predictive Forecast Models
Nexien Biopharma's time-series forecasting models is one of many Nexien Biopharma's pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Nexien Biopharma's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about Nexien Biopharma
Checking the ongoing alerts about Nexien Biopharma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Nexien Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Nexien Biopharma is way too risky over 90 days horizon | |
| Nexien Biopharma has some characteristics of a very speculative penny stock | |
| Nexien Biopharma appears to be risky and price may revert if volatility continues | |
| Nexien Biopharma has high likelihood to experience some financial distress in the next 2 years | |
| Nexien Biopharma currently holds 221.73 K in liabilities with Debt to Equity (D/E) ratio of 0.36, which is about average as compared to similar companies. Nexien Biopharma has a current ratio of 0.5, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Nexien Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Nexien Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Nexien Biopharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Nexien to invest in growth at high rates of return. When we think about Nexien Biopharma's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (626.36 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Nexien Biopharma currently holds about 116.9 K in cash with (75.14 K) of positive cash flow from operations. | |
| Roughly 54.0% of Nexien Biopharma outstanding shares are owned by corporate insiders |
Other Information on Investing in Nexien Pink Sheet
Nexien Biopharma financial ratios help investors to determine whether Nexien Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nexien with respect to the benefits of owning Nexien Biopharma security.